Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Surfacide experiences 500% Increase in Demand of Their Coronavirus Killing UV Robots

(Waukesha, WI)—January 5, 2021 – Surfacide®, the leader in hospital-grade, triple-emitter UV-C robot technology, is excited to announce they’ve moved to a larger facility in Waukesha, WI to accommodate rapid business growth at more than 500% in the past year. As we move into our new normal, germ-fighting, COVID-19 killing “robots” is being deployed everywhere…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share
Surfacide experiences 500% Increase in Demand of Their Coronavirus Killing UV Robots

(Waukesha, WI)—January 5, 2021 – Surfacide®, the leader in hospital-grade, triple-emitter UV-C robot technology, is excited to announce they’ve moved to a larger facility in Waukesha, WI to accommodate rapid business growth at more than 500% in the past year. As we move into our new normal, germ-fighting, COVID-19 killing “robots” is being deployed everywhere from hospitals, nursing homes, restaurants, hotels, gyms to commercial office spaces, tourist attractions, and professional sports stadiums. Surfacide has been a trusted leader in UV decontamination for over ten years due to its world’s only patented Helios® Triple-Emitter System of three virus-zapping robots.

Surfacide is actively being used throughout the world in over 500 leading healthcare facilities, children’s hospitals, nursing homes, correctional facilities, dental offices, hotels, restaurants, commercial businesses and more around the world. Such facilities include the Seattle Space Needle, Beachbody Studios, Children’s Hospital of Los Angeles and locally at Children’s Hospital of Wisconsin, Froedtert Medical College—Milwaukee and Aspirus Wausau Hospital. The company’s UV-C technology is scientifically validated to inactivate coronavirus–the family of virus that make up SARS-CoV-2 and COVID-19.

Surfacide’s new location is at N918 Northmound Dr., STE. 300 Waukesha, WI 53186 and the company’s new facility is more than 75,000 sq-ft, three times the size of their previous location. The company was started in a one-room office in 2010 and has experienced incredible and consistent growth every year since its inception. The expansive new building space will offer much needed space for Surfacide’s expanding team and to meet the huge increase in demand for their UV system since the pandemic hit. The facility will continue to house the company’s manufacturing and distribution arm, as well as a global training center, a state-of-the-art UV robot simulation room, conference rooms and offices.

Gunner Lyslo, Founder & CEO of Surfacide shares his excitement for the new space: “During the pandemic, we are fortunate to have grown our team and provide a proven UV-C technology that has tremendously impacted healthcare facilities, nursing homes, dental offices, and more in fighting the COVID-19 virus,” says Lyslo. “This year the importance of infection prevention has been paramount, and we expect to see that course continue in years to come. For as long as our communities need safety and protection, Surfacide will continue to evolve and be there to assist those who need it most.”

 About Surfacide

 Surfacide LLC and Surfacide Manufacturing Inc. are located in Waukesha, WI and produce multiple emitter UV-C systems. Surfacide is the only patented triple emitter UV-C system, providing the most efficient and flexible solution in the fight against viruses and bacteria that cause hospital-acquired infections. Hundreds of hospitals worldwide are using Surfacide technology to provide an extra layer of protection for patients and healthcare workers. Surfacide’s evidence-based UV-C solution reaches more surfaces, reduces shadowed areas, and requires less labor for a quicker turnaround time and better efficacy. Learn more about Surfacide by visiting https://surfacide.com or calling (844)-390-3538.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

IQVIA's new white paper maps how digital health technologies can reshape CNS clinical trial endpoints

IQVIA's new white paper maps how digital health technologies can reshape CNS clinical trial endpoints

IQVIA's white paper provides a framework for validating digital endpoints in CNS clinical trials, focusing on digital health technologies such as sensors, software, and connected devices. These technologies have the potential to reshape clinical trial endpoints in neurological studies. The white paper aims to guide the integration of digital health solutions in measuring clinical outcomes.

  • 01Digital health technologies like sensors and software can reshape CNS clinical trial endpoints.
  • 02Validating digital endpoints in clinical trials is crucial for integrating technology in CNS studies.
  • 03IQVIA offers a framework for using connected devices in clinical research.

Jul 16, 2026

Clinical AI safety, intelligent ventilators, and payment accuracy: health tech's big moves on July 15

Clinical AI safety, intelligent ventilators, and payment accuracy: health tech's big moves on July 15

On July 15, significant health technology announcements highlighted advancements in AI safety benchmarks, smarter critical-care equipment, and autonomous front-office tools. These developments indicate a strong push towards integrating intelligent systems in healthcare to enhance patient care and operational efficiency.

  • 01AI safety benchmarks are being established to ensure intelligent technologies are safely integrated into healthcare systems.
  • 02Intelligent ventilators and smarter critical-care tools are being developed to improve patient outcomes in healthcare settings.
  • 03Autonomous front-office tools are being introduced to streamline administrative tasks in healthcare facilities.

Jul 16, 2026

Saudi Arabia's digital health push: what a $77 billion market means for enterprise operators

Saudi Arabia's digital health push: what a $77 billion market means for enterprise operators

Saudi Arabia is set to expand its healthcare market with expenditures predicted to reach $77.1 billion by 2027, partly driven by advancements in digital health technologies. Digital health revenue is expected to exceed $1 billion by 2029, with an anticipated user base of 16.2 million. This growth represents significant opportunities for enterprise operators in the healthcare sector.

  • 01Saudi Arabia's healthcare spend is projected to reach $77.1 billion by 2027.
  • 02The digital health market in Saudi Arabia is expected to generate over $1 billion in revenue by 2029.
  • 03An estimated 16.2 million users will engage with digital health services in Saudi Arabia by 2029.

Jul 16, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512